🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Analysis of Growth Differentiation Factor 15 (GDF-15), Mid Regional proAdrenomedullin (MR proADM), and Persepsin Levels in Patient in Acute Coronary Syndrome Patients With Pneumonia, With or Without Influenza Vaccination

RecruitingPhase 3Ages 18 Years - 65 YearsAllUniversity of Brawijaya
NCT07604103 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The goal of this observational study is to analyze the relationship between various biomarkers (GDF-15, MR proADM, and Presepsin) in patients with Acute Coronary Syndrome (ACS) who also have Pneumonia and Chronic Obstructive Pulmonary Disease (COPD) and have received Influenza vaccinations. The main questions it aims to answer are: * Is there a significant correlation between the levels of these specific biomarkers and the clinical outcomes or inflammatory status of these patients? * How does Influenza vaccinations relate to the levels of these biomarkers in the context of ACS with comorbid respiratory conditions? Researchers will compare the levels of these biomarkers across the participant group to see if they can serve as indicators of the patients' health status or the impact of the vaccinations. Participants will: \- Undergo clinical assessment for Acute Coronary Syndrome, Pneum

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Adult male patients (\< 65 years old). * History of being an active smoker. * Confirmed diagnosis of Acute Coronary Syndrome (ACS) and Pneumonia based on clinical, laboratory, and radiological criteria. * Demonstrated clinical improvement (stabilization) after receiving standard ACS and Pneumonia therapy in the acute intrahospital phase. * Willing to undergo all study procedures and sign the Informed Consent form. Exclusion Criteria: * Presence of absolute contraindications to pneumococcal and influenza vaccination (history of anaphylactic reactions to vaccine components). * Patients with malignancies (cancer), systemic autoimmune diseases, or those currently on long-term immunosuppressant therapy. * Patients with End-Stage Renal Disease (ESRD) or severe liver dysfunction that could confound inflammatory biomarker values. * Patients with persistently unstable hemodynamic conditions or unresolved cardiogenic shock during the acute care phase. * Patient death before the observation period (up to post-vaccination) is completed. * Patient unilaterally resigns or withdraws consent during the study. * Lost to follow-up during scheduled outpatient clinic visits or scheduled follow-up biomarker evaluations.
💊

What it tests

  • Vaxigrip
  • antibiotic treatments
  • percutaneus coronary intervention
📍

Where

1 site
RSUD Dr. Saiful Anwar
Malang, Indonesia
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy